Aardvark Therapeutics Inc. (NASDAQ:AARD) shares are down during Monday’s premarket session following the company’s announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.The decision comes as the company is conducting a comprehensive review of safety data.Observed Side EffectsThe company on Friday revealed that it will not announce topline data from the HERO trial as previously anticipated in the third quarter of 2026. This pause was prompted by reversible cardiac observations at ...